Top generic drugs maker, Bosnalijek, expects a rise of more than 15 percent in net profits this year after an 11 percent gain in 2012 on growing exports, its general manager said on Wednesday.
Nedžad Polić said Bosnalijek last year posted a net profit of 6.55 million BAM on sales up 5 percent at 111.8 million BAM.
Its exports, mainly to Russia, amounted to more than 65 million BAM or more than 10 percent up from last year.
“This is the second year in a row in which sales on international markets exceed those made on the domestic market,” Polić told reporters, adding that Bosnalijek will remain focused on developing its international business.
He forecast a rise in sales of 15 percent this year and 11 percent and 10 percent in 2014 and 2015, respectively.
Bosnalijek plans to invest 90 million BAM to improve its drugs quality control system to meet international standards and build a new line for non sterile drugs compounding, Polić said.
